Lexeo Therapeutics updates on LX2006 and LX2020 trials with positive interim Phase 1/2 results

From GlobeNewswire: 2024-11-13 07:30:00

Lexeo Therapeutics has reached alignment with the FDA on key elements of the development plan for LX2006, with LVMI and frataxin protein expression as co-primary endpoints. The company also received RMAT designation for LX2006 for Friedreich ataxia cardiomyopathy. Enrollment in trials for LX2006 and LX2020 has been completed. Cash and cash equivalents stand at $157.0 million.

The completion of enrollment in the SUNRISE-FA Phase 1/2 trial for LX2006 and cohort 1 of the HEROIC-PKP2 Phase 1/2 trial for LX2020 is a significant milestone for Lexeo Therapeutics. The company expects initial clinical data for LX2020 in late Q1/early Q2 2025. Additionally, the appointment of Tolga Tanguler to the Board of Directors brings valuable experience to the team.

Lexeo Therapeutics remains focused on advancing treatments for genetically defined cardiovascular diseases and APOE4-associated Alzheimer’s disease. The company’s progress with LX2006 and LX2020 trials, along with positive interim Phase 1/2 results for LX1001, demonstrates its commitment to developing innovative therapies. With a cash position of $157.0 million, Lexeo is well-positioned for future growth and development.



Read more at GlobeNewswire:: Lexeo Therapeutics Provides Update on Cardiac Portfolio and